Can-Fite BioPharma Ltd. (CANF) DCF Valuation

Can-Fite BioPharma Ltd. (CANF) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Can-Fite BioPharma Ltd. (CANF) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Discover the true potential of Can-Fite BioPharma Ltd. (CANF) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how changes influence Can-Fite BioPharma Ltd. (CANF) valuation – all within a single Excel template.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 2.0 .8 .9 .8 .7 .6 .5 .4 .4 .3
Revenue Growth, % 0 -62.45 11.8 -5.04 -8.27 -15.99 -15.99 -15.99 -15.99 -15.99
EBITDA -12.0 -14.1 -12.8 -10.1 -8.2 -.6 -.5 -.4 -.4 -.3
EBITDA, % -590.21 -1851.51 -1503.87 -1244.69 -1100.94 -100 -100 -100 -100 -100
Depreciation .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Depreciation, % 0.68893 1.57 1.64 1.73 2.02 1.53 1.53 1.53 1.53 1.53
EBIT -12.0 -14.1 -12.8 -10.1 -8.2 -.6 -.5 -.4 -.4 -.3
EBIT, % -590.9 -1853.08 -1505.51 -1246.42 -1102.96 -100 -100 -100 -100 -100
Total Cash 2.8 8.3 19.1 8.0 8.9 .6 .5 .4 .4 .3
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 0 2.36 5.63 5.8 0
Inventories .0 1.0 .0 .0 .0 .1 .1 .1 .1 .1
Inventories, % 0 126.34 -5.63 -4.81 0 17.91 17.91 17.91 17.91 17.91
Accounts Payable 2.2 .6 1.0 .9 .4 .5 .5 .4 .3 .3
Accounts Payable, % 106.1 73.53 111.84 110.62 57.47 86.2 86.2 86.2 86.2 86.2
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % -0.14764 -3.41 -1.29 -1.11 -0.26918 -1.25 -1.25 -1.25 -1.25 -1.25
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -12.0 -14.1 -12.8 -10.1 -8.2 -.6 -.5 -.4 -.4 -.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -9.8 -16.7 -11.5 -10.2 -8.6 -.6 -.6 -.5 -.4 -.3
WACC, % 7.29 7.29 7.29 7.29 7.29 7.29 7.29 7.29 7.29 7.29
PV UFCF
SUM PV UFCF -2.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value -7
Present Terminal Value -5
Enterprise Value -7
Net Debt -4
Equity Value -3
Diluted Shares Outstanding, MM 4
Equity Value Per Share -0.60

What You Will Get

  • Real CANF Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
  • Scenario Analysis: Explore various scenarios to assess Can-Fite BioPharma's future performance.
  • User-Friendly Design: Tailored for experts but easy to navigate for newcomers.

Key Features

  • Customizable Clinical Parameters: Adjust essential inputs such as trial success rates, market penetration, and R&D costs.
  • Instant DCF Valuation: Automatically computes intrinsic value, NPV, and related metrics in real-time.
  • High Precision Results: Leverages Can-Fite's actual financial data for credible valuation insights.
  • Effortless Scenario Testing: Evaluate various assumptions and analyze results with ease.
  • Efficiency Booster: Streamline the valuation process without the hassle of complex model creation.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based CANF DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other parameters.
  3. Instant Calculations: The model automatically recalculates Can-Fite BioPharma's intrinsic value.
  4. Test Scenarios: Experiment with different assumptions to assess potential valuation variations.
  5. Analyze and Decide: Utilize the results to inform your investment or financial analysis.

Why Choose Can-Fite BioPharma Ltd. (CANF)?

  • Innovative Solutions: Focuses on developing advanced therapies for cancer and autoimmune diseases.
  • Robust Pipeline: Features a diverse range of clinical-stage assets with promising results.
  • Expert Team: Led by industry veterans with extensive experience in biotechnology and pharmaceuticals.
  • Strong Partnerships: Collaborates with leading institutions and organizations to enhance research and development.
  • Market Potential: Positioned in high-demand therapeutic areas with significant growth opportunities.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Can-Fite BioPharma Ltd. (CANF) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models for Can-Fite BioPharma Ltd. (CANF).
  • Consultants: Deliver professional valuation insights on Can-Fite BioPharma Ltd. (CANF) to clients quickly and accurately.
  • Business Owners: Understand how biotech companies like Can-Fite BioPharma Ltd. (CANF) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios focused on Can-Fite BioPharma Ltd. (CANF).

What the Template Contains

  • Historical Data: Includes Can-Fite BioPharma Ltd.’s (CANF) past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Can-Fite BioPharma Ltd.’s (CANF) intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Can-Fite BioPharma Ltd.’s (CANF) financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.